title: [Treatment side effects and follow-up of malignant melanoma].
abstract: Side effects in the therapy of malignant melanoma are primarily of importance for radiologists in advanced tumor stages. The available treatment options and their respective side effect profiles have undergone a profound change in recent years after the introduction of modern oncological therapies (e.g. immunotherapy and targeted therapy) with an increasing focus on individual tumor biology and differ significantly from those of classical chemotherapy. The immunotherapeutic agents, in particular ipilimumab, take on a special position because of their specific immune-mediated mechanisms of action and the associated side effects, so-called immune-related adverse events (irAE). The majority of the treatment effects are manifested on the skin (> 50 %) and are generally not detectable by diagnostic radiology. Only a comparatively small proportion of treatment side effects is detectable with diagnostic imaging (15-20 %) but as in the example of therapy-induced colitis with ipilimumab, may be rapidly fatal. In addition to colitis (10-20 %) further therapy side effects apparent in diagnostic imaging are hypophysitis (1.8-17 %), thyroiditis (0.8 %), myositis (1.7 %), fasciitis and sarcoid-like lymph node alterations (6.8 %). To detect radiologically detectable side effects early on and to delineate them especially from tumor progression and (opportunistic) infections, detailed knowledge of the therapeutic methods for melanoma, the mechanisms of action and in particular the sometimes very specific side effects is imperative for radiologists.
authors: Zentralinstitut für diagnostische und interventionelle Radiologie, Klinikum der Stadt Ludwigshafen gGmbH, Bremserstr. 79, 67063, Ludwigshafen, Deutschland, stahlt@klilu.de.
authors: T
authors: T
authors: Stahl
authors: C
authors: C
authors: Loquai
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003937:Diagnosis, Differential; D003952:Diagnostic Imaging / Q000379:methods*; D016903:Drug Monitoring / Q000379:methods; D006801:Humans; D007249:Inflammation / Q000139:chemically induced* / Q000175:diagnosis*; D008545:Melanoma / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents
references: J Natl Cancer Inst. 2011 Jan 19;103(2):129-42
references: 21081714
references: Radiographics. 2006 Mar-Apr;26(2):481-95
references: 16549611
references: Hautarzt. 2014 Jul;65(7):582-9
references: 24903029
references: Onco Targets Ther. 2010 Jun 24;3:15-25
references: 20616954
references: J Dtsch Dermatol Ges. 2011 Apr;9(4):277-86
references: 21083648
references: J Clin Oncol. 2012 Jul 20;30(21):2691-7
references: 22614989
references: AJR Am J Roentgenol. 2011 Dec;197(6):W992-W1000
references: 22109345
references: J Dtsch Dermatol Ges. 2012 Jul;10(7):475-86
references: 22571234
references: AJR Am J Roentgenol. 2013 Mar;200(3):475-83
references: 23436834
references: Nat Clin Pract Oncol. 2006 Jun;3(6):339-43; quiz following 343
references: 16757971
references: Clin Cancer Res. 2009 Dec 1;15(23 ):7412-20
references: 19934295
references: Eur J Endocrinol. 2012 Jul;167(1):1-5
references: 22495490
references: J Clin Oncol. 2012 Feb 20;30(6):e76-8
references: 22203769
references: AJR Am J Roentgenol. 2011 Aug;197(2):W241-6
references: 21785048
references: J Dtsch Dermatol Ges. 2011 Mar;9(3):212-22
references: 21352483
references: N Engl J Med. 2011 Jun 30;364(26):2507-16
references: 21639808
references: Eur J Cancer. 2007 Feb;43(3):557-64
references: 17224266
references: JAMA Dermatol. 2013 Oct;149(10 ):1242-3
references: 23986488
references: Br J Dermatol. 2012 Nov;167(5):987-94
references: 22913467
references: Cancer. 1998 May 1;82(9):1664-71
references: 9576286
references: Clin Cancer Res. 2009 Sep 1;15(17 ):5591-8
references: 19671877
references: PLoS One. 2013;8(1):e53745
references: 23341990
references: Scientifica (Cairo). 2013;2013:857519
references: 24278787
references: Melanoma Res. 2014 Oct;24(5):512-6
references: 24743051
references: Am J Hematol. 2006 Mar;81(3):189-92
references: 16493605